

TABLE OF CONTENTS

April 6, 2009

No. 2134

BUSINESS

- 1 Synergism with Millennium to Drive Takeda's Business in Oncology
 - Aiming at IND Filing for 3 or 4 Compounds per Year: Dr Dunsire
 - Vectibix to Reach Japanese Market in 2010
- 2 Meiji Seika Licenses Drug for Schizophrenia from ACADIA
- 3 Eli Lilly Japan: Sales Up 2% to ¥91,773 Mil.
- 3 Mr Matsutani to Step Down as FJPWA President
 - Wholesale Business Practices Must Be Reformed
 - Stronger Leader Is Necessary
- 4 **NEW PRODUCTS**
 - Pfizer Japan: Single-Dose Zithromac SR Dry Syrup
 - Otsuka: Abilify Oral Solution 0.1%
 - Bristol-Myers: Sprycel for CML and ALL
- 5 **BUSINESS NEWS IN BRIEF**
 - Takeda Takes Back Marketing Right for Prostag from Wyeth in UK
 - Alfresa Revises Its Business Forecasts Downward

GENERICIS

- 6 Market Growth for Generics Slowed Down in 4th Qtr of 2008
 - Maintain the 70% Price Rule for First Generics
- 6 1st Seminar to Promote Use of Generics Held
- 7 *Koroshō's* Survey Confirms Low Generic Substitution Rate
 - NHI Prices of New Drugs Should Be Cut to Levels of Generics When They Go Off-Patent
- 8 78.6% of Pharmacies Obtain Premium for Dispensing Generics
 - Non-DPC Hospitals Use Generics More Enthusiastically than DPC Hospitals
- 9 Daiichi Sankyo Sues 13 Companies for Levofloxacin Patent Violation
- 9 Many Patients Hesitate to Request Generic Substitution

COMMENTARY

- 10 The First Round Results of GE Amlodipine (2): Sugio Seko

REGULATORY

- 14 12 Drugs and 5 APIs Priced
- 14 Falsification of Data Found on World's 1st Recombinant Human Albumin
 - *Koroshō* to Undertake Investigations
- 15 **REGULATORY NEWS IN BRIEF**
 - Coadministration of Actos with Insulin Approved

- FDA Advisory Committee Supports Favorable Risk-Benefit Profile of Rivaroxaban

R&D

- 16 LDP's Research Commission Calls For More Investment in Pharma R&D
- 16 **R&D NEWS IN BRIEF**
 - Bendamustine Gives Higher-Than-Expected Response Rates: SymBio
 - 90% of Herceptin-treated Women Alive after 4 Years: Roche
 - Arimidex Reduces Risk of Postoperative Breast Cancer Recurrence: AZ
 - Oncolys BioPharma to Supply Telomelysin to Okayama Univ. Hospital

MEDICAL FACILITIES & NURSING CARE

- 17 7th JSMO Annual Meeting
 - NDA for Lenalidomide to Be Filed in Japan in April
 - Overall Survival Data from NSCLC Patients Treated with Iressa Expected in 2010
 - Trials Underway to Expand Indications of Velcade
 - Palonosetron Effective against CINV in PIII Trial in Japan
- 18 Aggregates Not Visible with Naked Eye Detected in Kenacort
- 19 Pfizer Announces Results of EPPV on Sutent
 - Dosage Regimen May Have to Be Reviewed
- 20 Greater Hypotensive Effects Can Be Expected with Co-DIO: Dr Ogihara
 - Fixed-Dose Combination Drugs Improve Adherence
- 20 Selective α 1-Inhibitors Effective against MS-Associated Dysuria: Prof. Horie
- 21 Treatment of AD/HD Has Reached a Stalemate: Prof. Tanaka
- 21 **TOPICS**
 - JSHP Concerned about Exposure of Pharmacists to Anticancer Drugs
- 22 Increases in People's Financial Burden Are Inevitable: MOF
- 22 **Survey**
 - Awareness Rate for CKD only 10%: Healthclick
 - Cancer Patients will Increase to 780,000 by 2015: CareNet

MEDICAL DEVICES

- 23 JSMO Aims at Health Insurance Coverage of KRAS Gene Testing
- 23 UGT1A1 Gene Polymorphism Testing Reagent from Sekisui Medical